Can a new drug target HER2-Positive tumors that resist standard care?
NCT ID NCT06516926
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This phase II trial is testing an experimental drug called SHR-4602 in people with advanced solid tumors that have HER2 expression or mutations. The drug is given by infusion every three weeks. The study aims to see if SHR-4602 can shrink tumors and how safe and tolerable it is. Participants must have measurable disease and be in generally good health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-4602, an experimental antibody-drug conjugate given by intravenous infusion every 21 days
- What this could lead to
- If effective, SHR-4602 could offer a new treatment option for people with advanced solid tumors that express or have mutations in HER2, potentially shrinking tumors and delaying progression.
- What could go wrong
- This is an early-phase, small study (11 participants) focused on safety and preliminary efficacy. The drug may not work in all patients, and side effects could be significant. Results are not yet available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-EXPRESSING OR -MUTATED UNRESECTABLE OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China